The latest price target for Gain Therapeutics (NASDAQ:GANX) was reported by HC Wainwright & Co. on December 19, 2025. The analyst firm set a price target for $8.00 expecting GANX to rise to within 12 months (a possible 321.05% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Gain Therapeutics (NASDAQ:GANX) was provided by HC Wainwright & Co., and Gain Therapeutics reiterated their buy rating.

There is no last upgrade for Gain Therapeutics

There is no last downgrade for Gain Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gain Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gain Therapeutics was filed on December 19, 2025 so you should expect the next rating to be made available sometime around December 19, 2026.

While ratings are subjective and will change, the latest Gain Therapeutics (GANX) rating was a reiterated with a price target of $8.00 to $8.00. The current price Gain Therapeutics (GANX) is trading at is $1.90, which is out of the analyst’s predicted range.